By Elise Reuter
Published: November 6, 2026
Tandem Diabetes Care, a pioneer in insulin delivery technology, has announced a major leadership transition. On Thursday, the company officially confirmed that Jeannette Bankes, a seasoned executive with over three decades of experience in the medical technology sector, will step into the role of President and Chief Executive Officer. Bankes is set to assume the position on November 16, succeeding long-time CEO John Sheridan, who announced his intention to retire at the end of the year.
The transition marks the end of a pivotal era for the San Diego-based manufacturer, which has transformed from a niche player into a central figure in the automated insulin delivery market under Sheridan’s leadership. As Bankes prepares to take the helm, the company stands at a critical juncture, balancing the finalization of new, advanced product pipelines with the need to maintain growth in an increasingly competitive diabetes technology landscape.
The Succession: A Strategic Handover
The decision to appoint Bankes, who currently serves as the CEO of GE HealthCare’s $3.1 billion patient care solutions business, was the result of a deliberate, long-term search process involving the Tandem board of directors. Bankes brings extensive expertise in product innovation and market scaling, having overseen a diverse portfolio at GE HealthCare that included monitoring, diagnostic cardiology, and anesthesia products.
For John Sheridan, the timing of the transition reflects both personal milestones and institutional stability. During a Thursday earnings call, the 70-year-old executive addressed his departure with characteristic candor. "I’m 70, and I’ve got to make a decision at some point," Sheridan remarked, emphasizing that he and the board had been working diligently to ensure a seamless leadership transition.
Sheridan, who joined Tandem in 2013 as Chief Operating Officer before ascending to the CEO role in 2019, expressed full confidence in his successor. He noted that Bankes’ deep background in global franchises—most notably her tenure as president of global franchises at Alcon—positioned her uniquely to navigate the complexities of the medical device market. To ensure continuity, Sheridan will remain with the company as an employee through the end of December and will transition into a consultancy role thereafter.
A Legacy of Innovation: The Sheridan Era
John Sheridan’s tenure as CEO is defined by the company’s aggressive pursuit of the "hybrid closed-loop" market. When he took the reins in 2019, the diabetes industry was just beginning to realize the potential of algorithms that could automatically adjust insulin delivery based on continuous glucose monitor (CGM) readings.
Under his leadership, Tandem successfully launched its first hybrid closed-loop technology, which significantly altered the standard of care for patients with Type 1 diabetes. Perhaps most notably, Sheridan oversaw the development and market introduction of the Tandem Mobi—the world’s smallest durable insulin pump. The Mobi was designed to address the "device fatigue" often felt by users, offering a discreet, tubed system that could be controlled via smartphone.
Sheridan leaves behind a "to-do" list that he believes is already well underway. Among his key strategic priorities were:
- The Tubeless Pivot: Expanding the Mobi platform to include a fully tubeless option.
- Automated Systems: Moving beyond "hybrid" systems toward a fully closed-loop automated insulin delivery (AID) solution.
- Channel Optimization: Developing robust coverage through the pharmacy channel to streamline patient access and reimbursement.
"I feel very confident that these things are moving in the right direction," Sheridan told investors, signaling that the structural foundation for these initiatives is firmly in place for Bankes to execute.
The Road Ahead: Product Pipeline and FDA Milestones
Jeannette Bankes inherits a company that is currently deep in the throes of regulatory and clinical development. The most immediate milestone on the horizon is the FDA review of the "Mobi Tubeless" pump. This product represents a critical strategic shift for Tandem, allowing it to compete more directly with patch-pump manufacturers that have traditionally dominated the tubeless segment of the market.
Furthermore, Tandem is pushing the boundaries of diabetes management through a collaborative project with the University of Virginia. The goal is to create a fully closed-loop system—a "set-it-and-forget-it" model—that would allow individuals with Type 1 and Type 2 diabetes to maintain target glucose levels without requiring manual input or "meal announcements." While the system will maintain manual override features for safety and user preference, the ambition is to automate the bulk of glycemic control. Tandem plans to initiate a pivotal study for this technology before the end of the year, a move that will likely be one of the first major operational tests for Bankes.
Executive Compensation and Market Implications
According to regulatory filings released on the heels of the announcement, Bankes will receive an annual base salary of $900,000. This compensation structure highlights the board’s commitment to securing top-tier leadership capable of navigating the high-stakes world of medical technology.
Investors have reacted with interest to the leadership change, as Tandem seeks to maintain its momentum in a sector where product iteration cycles are rapid and regulatory hurdles are significant. With the pharmacy channel continuing to evolve, Bankes’ experience in managing large-scale global businesses will be tested as she looks to solidify Tandem’s footprint against competitors such as Insulet and Medtronic.
Implications for the Diabetes Community
The implications of this leadership change extend far beyond the boardroom. For patients living with diabetes, the stability of Tandem’s leadership ensures that the transition from a tubed to a tubeless world—and eventually to a fully automated one—remains a priority.
Bankes’ appointment is viewed by many analysts as a signal that Tandem intends to shift its focus from "startup-style" rapid innovation to "enterprise-grade" operational excellence. Her background at GE HealthCare and Alcon suggests a focus on operational efficiency and market expansion, which are essential as Tandem moves from being a specialized pump manufacturer to a comprehensive digital health provider.
As Tandem enters this new chapter, the focus will remain on whether the company can maintain its culture of user-centric design while scaling its infrastructure to meet the demands of an aging, technology-reliant patient population. Bankes, with her proven track record of driving growth and profitability in complex medical business units, appears poised to lead the company through this transition.
As the industry watches, the departure of a figure as impactful as John Sheridan marks the end of a formative decade for the company. However, the appointment of Jeannette Bankes suggests that Tandem is not looking back, but rather accelerating toward the next frontier of diabetes management. With the Mobi Tubeless filing in late-stage review and the pivotal study for the fully closed-loop system imminent, the company remains at the forefront of the digital health revolution, ready to face the challenges of 2027 and beyond.
